user

Idelalisib monotherapy results in durable responses in patients with relapsed or refractory Waldenstrom's macroglobulinemia (WM)

被引：0
|
作者：
Coutre, S. [1 ]
Leonard, J. [2 ]
Flowers, C. [3 ]
Davies, A. [4 ]
Jurczak, W. [5 ]
Byrd, J. [6 ]
Spurgeon, S. [7 ]
Peterman, S. [8 ]
Holes, L. [8 ]
Cho, Y. [8 ]
Sorenson, B. [8 ]
Godfrey, W. [8 ]
Gopal, A. [9 ]
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Weill Cornell Med Ctr, New York, NY USA
[3] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[4] Southampton Gen Hosp, Southampton, Hants, England
[5] Malopolskie Ctr Med SC, Krakow, Poland
[6] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[7] Oregon Hlth & Sci Univ, Portland, OR USA
[8] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[9] Univ Washington, Sch Med, Seattle, WA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2016年 / 173卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
246
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [31] Acalabrutinib in patients (pts) with Waldenstrom macroglobulinemia (WM).
    Owen, Roger
    McCarthy, Helen
    Rule, Simon
    D'Sa, Shirley
    Thomas, Sheeba K.
    Forconi, Francesco
    Anderson, Thomas C.
    Kersten, Marie Jose
    Zinzani, Pier Luigi
    Iyengar, Sunil
    Kothari, Jaimal
    Minnema, Monique
    Kastritis, Efstathios
    Izumi, Raquel
    Slatter, J. Greg
    Mittag, Diana
    Wei, Helen
    Chen, Dih-Yih
    Patel, Priti
    Furman, Richard R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] MODELLING THE EFFECTIVENESS OF IBRUTINIB VERSUS PHYSICIAN'S CHOICE (PC) IN RELAPSED OR REFRACTORY (RR) WALDENSTROM'S MACROGLOBULINEMIA (WM) WITHIN ENGLAND
    Guillermin, A.
    Hassan, R.
    Sydnor, S.
    Peng, S.
    Proskorovsky, I
    Sorensen, S.
    Thompson, G.
    Lee, J.
    VALUE IN HEALTH, 2017, 20 (09) : A442 - A442
  • [33] Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstrom's macroglobulinemia (WM): Results in 25 patients
    Vargaftig, J.
    Pegourie-Bandelier, B.
    Mahe, B.
    Le Gouill, S.
    Brottier-Mancini, E.
    Delarue, R.
    Buzyn, A.
    Maigre, M.
    Gardin, C.
    Choquet, S.
    Leblond, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 227 - 227
  • [34] Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinemia
    Wagner-Johnston, Nina D.
    Schuster, Stephen J.
    de Vos, Sven
    Salles, Gilles A.
    Jurczak, Wojciech
    Rajakumaraswamy, Nishan
    Xing, Guan
    Gopal, Ajay K.
    BLOOD, 2019, 134
  • [35] A PHASE II STUDY OF THE COMBINATION OF OFATUMUMAB WITH FLUDARABINE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA
    Gavriatopoulou, M.
    Roussou, M.
    Fotiou, D.
    Ziogas, D.
    Terpos, E.
    Kalapanida, D.
    Kafantari, E.
    Papathoma, A.
    Spyropoulou-Vlachou, M.
    Dimopoulos, M. A.
    Kastritis, E.
    HAEMATOLOGICA, 2016, 101 : 478 - 478
  • [36] Survival trends in young patients with Waldenstrom macroglobulinemia (WM).
    Vallumsetla, Nishanth
    Paludo, Jonas
    Gertz, Morie
    Ansell, Stephen Maxted
    Go, Ronald S.
    Rajkumar, Vincent
    Kyle, Robert A.
    Buadi, Francis
    Dispenzieri, Angela
    Lacy, Martha
    Dingli, David
    Hayman, Suzanne R.
    Leung, Nelson
    Kumar, Shaji
    Kapoor, Prashant
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Impact of Rituximab On the Treatment of Waldenstrom's Macroglobulinemia (WM)
    Thomas, Sheeba K.
    Delasalle, Kay B.
    Shah, Jatin J.
    Wang, Luhua
    Orlowski, Robert Z.
    Weber, Donna M.
    BLOOD, 2012, 120 (21)
  • [38] Phase II trial of perifosine (KRX-0401) in relapsed and/or refractory Waldenstrom's macroglobulinemia: Preliminary results
    Ghobrial, I. M.
    Leleu, X.
    Treon, S. P.
    Nelson, M. B.
    Leduc, R.
    Warren, D.
    Soumerai, J.
    Ngo, H.
    Sportelli, P.
    Birch, R.
    Henderson, I. C.
    Richardson, P.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 226 - 226
  • [39] Fludarabine plus cyclophosphamide and rituximab (RFC) in Waldenstrom's macroglobulinemia (WM):: Results in 21 patients (pts).
    Vargaftig, Jacques
    Pegourie-Bandelier, Brigitte
    Mahe, Beatrice
    Le Gouill, Steven
    Brottier-Mancini, Elisabeth
    Delarue, Richard
    Buzyn, Agnes
    Raphael, Martine
    Choquet, Sylvain
    Leblond, Veronique
    BLOOD, 2006, 108 (11) : 264B - 264B
  • [40] Treatment options for relapsed Waldenstrom's Macroglobulinemia
    Grunenberg, Alexander
    Buske, Christian
    HEMASPHERE, 2019, 3 : 65 - 67
12345